SM 12502

Drug Profile

SM 12502

Alternative Names: SM-12502

Latest Information Update: 30 Aug 2007

Price : $50

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Class Antiplatelets
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Disseminated intravascular coagulation; Shock

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Shock in Japan (Unknown route)
  • 02 Oct 2001 No-Development-Reported for Disseminated intravascular coagulation in Japan (Unknown route)
  • 12 Jun 1997 A study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top